Mazdutide (Xinermei)
Also known as: Xinermei
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Innovent Biologics (licensed from Eli Lilly) |
| Mechanism | Dual agonist — GLP-1 + glucagon receptors |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~14–18% (Chinese Phase 3 program) |
| Status | Approved in China (Xinermei) 2025; US Phase 2 ongoing |
Deep dive
What Is Mazdutide (Xinermei)? The First GLP-1/Glucagon Drug Approved in China →The first GLP-1/glucagon dual agonist approved anywhere — how it works, what the trials show, and why it matters for the obesity drug landscape.
Mazdutide (Xinermei) compared
Every head-to-head we've published involving Mazdutide (Xinermei).
Mazdutide vs Retatrutide: Dual vs Triple Agonist Data 2026
How the triple agonist retatrutide compares to the dual agonist mazdutide on weight loss, diabetes, and liver fat data.
Updated August 18, 2026
Mazdutide vs Tirzepatide: GLP-1/Glucagon vs GLP-1/GIP Compared
Mazdutide pairs GLP-1 with glucagon for liver fat clearance. Tirzepatide pairs GLP-1 with GIP for maximum appetite suppression. Different second receptors, different strengths.
Updated February 2026
Mazdutide vs Survodutide: Two GLP-1/Glucagon Dual Agonists Compared
Both target GLP-1 and glucagon, but mazdutide is approved in China with best-in-class tolerability while survodutide leads on MASH liver data.
Updated March 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.